Phase II trial of AV 101 in patients with Parkinson's disease.
Latest Information Update: 28 Sep 2011
Price :
$35 *
At a glance
- Drugs AV 101 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 27 Sep 2011 Planned initiation date changed to 1 Oct 2012, according to a VistaGen Therapeutics media release.
- 19 Sep 2011 New trial record